A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
Latest Information Update: 19 Sep 2023
At a glance
- Drugs AMG-119 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 14 Sep 2023 Planned End Date changed from 13 Jan 2026 to 14 Jan 2027.
- 14 Sep 2023 Planned primary completion date changed from 13 Jan 2026 to 14 Jan 2027.
- 18 Mar 2022 Results assessing the cellular kinetics dose-exposure response of AMG119 therapy being evaluated for the treatment of patients with relapsed/refractory small cell lung cancer presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics